Streetbeat News

Analyst Ratings

NOVA

Jefferies has initiated coverage on Sunnova Energy Intl with a Buy rating and set a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:38 pm

MLSS

Benchmark analyst Bruce Jackson has initiated coverage on Milestone Scientific (AMEX:MLSS) with a Speculative Buy rating and set a price target of $1.25.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:38 pm

KYTX

UBS has initiated coverage on Kyverna Therapeutics with a Buy rating and set a price target of $13, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:34 pm

HUMA

Benchmark analyst Bruce Jackson has reiterated a Buy rating on Humacyte (NASDAQ:HUMA) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:33 pm

CABA

UBS has initiated coverage on Cabaletta Bio with a Buy rating and set a price target of $10, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:31 pm

META

Truist Securities has maintained its Buy rating on Meta Platforms and increased the price target from $570 to $650, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:23 pm

LLY

Truist Securities has maintained its Buy rating on Eli Lilly and raised the price target from $1000 to $1033, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:22 pm

BP

Scotiabank analyst Paul Cheng has downgraded BP from Sector Outperform to Sector Perform and reduced the price target from $42 to $36.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:21 pm

GDTC

Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on CytoMed Therapeutics (NASDAQ:GDTC) and maintained a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:19 pm

SAR

Ladenburg Thalmann analyst Mickey Schlelen has downgraded Saratoga Investment (NYSE:SAR) from Buy to Neutral, indicating a change in the analyst's outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:19 pm